🔗 Share this article

This year's prestigious award in Physiology or Medicine has been awarded for revolutionary discoveries that illuminate how the body's defense network targets harmful pathogens while sparing the healthy tissues.

A trio of renowned researchers—Japan's Shimon Sakaguchi and American experts Dr. Brunkow and Dr. Ramsdell—share this honor.

Their work identified specialized "sentinels" within the immune system that remove malfunctioning immune cells that could harming the organism.

The findings are now enabling innovative therapies for immune disorders and cancer.

The laureates will share a prize fund valued at 11 million Swedish kronor.

Decisive Discoveries

"Their research has been essential for comprehending how the immune system operates and why we don't all develop serious self-attack conditions," commented the head of the award panel.

The trio's studies address a fundamental question: In what way does the defense system protect us from countless infections while keeping our healthy cells unharmed?

Our immune system employs immune cells that search for indicators of infection, including viruses and germs it has never encountered.

Such defenders utilize detectors—known as recognition units—that are produced by chance in a vast number of variations.

This gives the defense network the capacity to fight a wide array of invaders, but the randomness of the mechanism inevitably produces white blood cells that can target the body.

Security Guards of the Body

Researchers earlier understood that a portion of these harmful defense cells were destroyed in the thymus—where white blood cells develop.

This year's Nobel Prize recognizes the discovery of T-reg cells—described as the immune system's "security guards"—which travel through the body to disarm other defenders that attack the healthy cells.

We know that this process fails in autoimmune diseases such as type-1 diabetes, MS, and RA.

A Nobel panel added, "These findings have established a novel area of research and spurred the development of new therapies, for example for cancer and autoimmune diseases."

Regarding cancer, T-regs prevent the system from attacking the growth, so studies are aimed at reducing their quantity.

For self-attack disorders, trials are testing increasing T-reg cells so the organism is not being harmed. A comparable method could also be effective in minimizing the chances of organ transplant rejection.

Pioneering Experiments

Professor Shimon Sakaguchi, of Osaka University, performed tests on mice that had their immune gland extracted, leading to autoimmune disease.

The researcher showed that injecting immune cells from other animals could prevent the disease—suggesting there was a mechanism for blocking defenders from attacking the host.

Mary Brunkow, affiliated with the a research center in a US city, and Dr. Ramsdell, currently at Sonoma Biotherapeutics in a California city, were investigating an inherited immune disorder in rodents and humans that led to the identification of a gene critical for how T-regs operate.

"Their pioneering research has revealed how the body's defenses is controlled by regulatory T cells, preventing it from accidentally targeting the healthy cells," commented a leading biological science expert.

"The research is a remarkable example of how fundamental physiological study can have broad implications for human health."